Nidufexor is an investigational small molecule drug belonging to the farnesoid X receptor (FXR) modulator class, currently studied for its potential to treat conditions involving liver and kidney fibrosis… Read more
Nidufexor is an investigational small molecule drug belonging to the farnesoid X receptor (FXR) modulator class, currently studied for its potential to treat conditions involving liver and kidney fibrosis by regulating bile acid metabolism and reducing oxidative stress and inflammation. As research into this therapeutic agent progresses, pharmaceutical laboratories rely on high-quality reference standards for comprehensive analytical testing and method validation. This category provides access to the active pharmaceutical ingredient (API), along with its identified pharmacopeial and non-pharmacopeial impurities, metabolites, and stable isotope-labelled compounds. These materials are essential for accurate impurity profiling, supporting the development of robust analytical methods, and ensuring rigorous quality control throughout the lifecycle of pharmaceutical formulations. By utilizing these precise reference materials, researchers can confidently characterize the drug substance and monitor degradation products during formulation development and stability studies.